US 11,744,845 B2
Compounds,compositions, and methods for the treatment of disease
Radhakrishnan P. Iyer, Shrewsbury, MA (US); Anjaneyulu Sheri, Shrewsbury, MA (US); Seetharamaiyer Padmanabhan, Lexington, MA (US); Geeta Meher, Hopkinton, MA (US); Shenghua Zhou, Shrewsbury, MA (US); Sreerupa Challa, Shrewsbury, MA (US); Rayomand H. Gimi, Chelmsford, MA (US); and Dillon Cleary, Norton, MA (US)
Assigned to F-star Therapeutics, Inc., Cambridge (GB)
Filed by F-star Therapeutics, Inc., Cambridge (GB)
Filed on Jun. 4, 2021, as Appl. No. 17/339,484.
Application 17/339,484 is a continuation of application No. 16/315,472, granted, now 11,033,569, previously published as PCT/US2017/040882, filed on Jul. 6, 2017.
Claims priority of provisional application 62/508,846, filed on May 19, 2017.
Claims priority of provisional application 62/470,746, filed on Mar. 13, 2017.
Claims priority of provisional application 62/462,679, filed on Feb. 23, 2017.
Claims priority of provisional application 62/444,141, filed on Jan. 9, 2017.
Claims priority of provisional application 62/411,424, filed on Oct. 21, 2016.
Claims priority of provisional application 62/403,530, filed on Oct. 3, 2016.
Claims priority of provisional application 62/363,118, filed on Jul. 15, 2016.
Claims priority of provisional application 62/359,039, filed on Jul. 6, 2016.
Prior Publication US 2022/0054523 A1, Feb. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7084 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); C07H 21/00 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01)
CPC A61K 31/7084 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0029 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07H 21/00 (2013.01); A61K 2039/55511 (2013.01)] 22 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.